Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)

China flag China · Delayed Price · Currency is CNY
43.32
+2.42 (5.92%)
Apr 29, 2026, 3:04 PM CST
Market Cap5.20B +115.6%
Revenue (ttm)688.74M +27.0%
Net Income44.38M +5.9%
EPS0.37 +6.0%
Shares Out120.00M
PE Ratio117.11
Forward PEn/a
Dividend0.10 (0.24%)
Ex-Dividend Daten/a
Volume7,574,500
Average Volume5,563,730
Open41.54
Previous Close40.90
Day's Range40.62 - 44.31
52-Week Range18.71 - 81.88
Beta0.29
RSI50.36
Earnings DateApr 25, 2026

About SHE:300584

Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company’s products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for injection; voglibose tablets, lansoprazole enteric-coated tablets, amlodipine besylate tablets, and glucosamine sulfate effervescent tablets/granules; ... [Read more]

Sector Healthcare
Founded 2003
Employees 548
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300584
Full Company Profile

Financial Performance

In 2025, SHE:300584's revenue was 671.05 million, an increase of 33.05% compared to the previous year's 504.36 million. Earnings were 42.06 million, an increase of 4.58%.

Financial Statements